Wild D - Search Results

1

Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.

Varum F, Thorne H, Bravo R, Gilgen D, Hartig C, Nicolas GP, Wild D, Liakoni E, Haschke M. Varum F, et al. Among authors: wild d. Int J Pharm. 2022 Sep 25;625:122055. doi: 10.1016/j.ijpharm.2022.122055. Epub 2022 Aug 1. Int J Pharm. 2022. PMID: 35926752 Free article.

2

Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.

Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D. Antwi K, et al. Among authors: wild d. J Nucl Med. 2015 Jul;56(7):1075-8. doi: 10.2967/jnumed.115.157768. Epub 2015 May 21. J Nucl Med. 2015. PMID: 25999434 Free article. Clinical Trial.

3

Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.

Baumann T, Rottenburger C, Nicolas G, Wild D. Baumann T, et al. Among authors: wild d. Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):45-57. doi: 10.1016/j.beem.2016.01.003. Epub 2016 Jan 20. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 26971843 Review.

4

Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷Lu-DOTATATE: The Mass Effect.

Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, Fani M. Nicolas GP, et al. Among authors: wild d. J Nucl Med. 2017 Sep;58(9):1435-1441. doi: 10.2967/jnumed.117.191684. Epub 2017 Apr 27. J Nucl Med. 2017. PMID: 28450554 Free article.

5

Somatostatin Receptor Antagonists for Imaging and Therapy.

Fani M, Nicolas GP, Wild D. Fani M, et al. Among authors: wild d. J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S. doi: 10.2967/jnumed.116.186783. J Nucl Med. 2017. PMID: 28864614 Free article. Review.

6

Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.

Nicolas GP, Wild D, Fani M. Nicolas GP, et al. Among authors: wild d. J Nucl Med. 2018 Mar;59(3):547-548. doi: 10.2967/jnumed.117.203703. Epub 2017 Nov 16. J Nucl Med. 2018. PMID: 29146693 Free article. No abstract available.

7

Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D. Nicolas GP, et al. Among authors: wild d. J Nucl Med. 2018 Jun;59(6):915-921. doi: 10.2967/jnumed.117.199760. Epub 2017 Nov 30. J Nucl Med. 2018. PMID: 29191855 Free article. Clinical Trial.

8

Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).

Valente LG, Antwi K, Nicolas GP, Wild D, Christ E. Valente LG, et al. Among authors: wild d. Swiss Med Wkly. 2018 Nov 18;148:w14682. doi: 10.4414/smw.2018.14682. eCollection 2018 Nov 5. Swiss Med Wkly. 2018. PMID: 30449018 Free article.

9

Molecular imaging for neuroendocrine tumours.

Antwi K, Nicolas G, Wild D, Christ E. Antwi K, et al. Among authors: wild d. Swiss Med Wkly. 2019 Mar 10;149:w20017. doi: 10.4414/smw.2019.20017. eCollection 2019 Feb 25. Swiss Med Wkly. 2019. PMID: 30852831 Free article. Review.

10

Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.

Antwi K, Nicolas G, Fani M, Christ E, Wild D. Antwi K, et al. Among authors: wild d. Clin Nucl Med. 2019 May;44(5):e347-e348. doi: 10.1097/RLU.0000000000002522. Clin Nucl Med. 2019. PMID: 30889001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

611 results

Search Page